MedTrace Logo

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

NCT01741142 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2013-10-08

No results posted yet for this study

Summary

The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.

Conditions

Interventions

DRUG

ABT-436

Subjects receiving ABT-436

DRUG

Escitalopram

Subjects receiving escitalopram

DRUG

Placebo

Subject receiving placebo

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Beatrice Rendenbach-Mueller, PhD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-10-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741142 on ClinicalTrials.gov